Sentence examples for most active chemotherapy from inspiring English sources

The combination of gemcitabine and cisplatin is one of the most active chemotherapy regimens against non-small cell lung cancer (NSCLC).

The most active chemotherapy agents in ovarian cancer are the platinum analogues, cisplatin and carboplatin.

Gemcitabine (difluorodeoxycytidine) is the most active chemotherapy agent used for the treatment of pancreatic cancer [ 3].

Taxanes are among the most active chemotherapy agents used in the management of metastatic breast cancer.

The most active chemotherapy regimens in the treatment of PSR EOC were reported with a median survival of 29 months (Parmar et al, 2003).

Berry and coworkers [ 65] reported the results of a combined analysis of the CALGB/Intergroup experience, suggesting that the benefit in favor of the most active chemotherapy regimens, in particular those containing paclitaxel, over the less aggressive ones is mostly limited to patients with ER-negative breast cancer.

The most active induction chemotherapy regimen in patients with unresectable SCC of the oropharynx is the combination of 5-fluorouracil (5-FU), docetaxel, and cisplatin (TPF) 6, 7.

The five-year survival rates after radical resection are 24 58% [ 1- 4], whereas the five-year survival rates for unresectable disease with most active systemic chemotherapy regimens are <5% [ 5].

Among the most active adjuvant chemotherapy regimens, the docetaxel-based combinations of docetaxel, doxorubicin, and cyclophosphamide (TAC), 6– 8 docetaxel with cyclophosphamide, 9, 10 sequential anthracycline (eg, FEC [5-fluorouracil, epirubicin, and cyclophosphamide]) followed by docetaxel monotherapy, 11– 14 and docetaxel, carboplatin, and trastuzumab 15 are most commonly used.

The present phase II study indicates that Raltitrexed has limited activity in patients that have failed the most active first-line chemotherapy regimen for ACC, incorporating weekly lrinotecan+5-FU+LV [ 6, 7].

In such patients, most of the active chemotherapy agents achieve overall response rates of 20 35% when given as monotherapy, with a median response duration of 3 6 months and a survival time of 5 9 months (Thigpen et al, 1981; McGuire et al, 1996).